A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventative Treatment of Episodic Migraine in Pe
Clinical Trial Grant
Awarded By
Teva Branded Pharmaceutical Products R&D, Inc
Start Date
January 4, 2022
End Date
January 7, 2025
Awarded By
Teva Branded Pharmaceutical Products R&D, Inc
Start Date
January 4, 2022
End Date
January 7, 2025